Could a simple infection in early infancy shape a child's lifelong breathing health? A new international study has uncovered a striking link between early respiratory infections and an increased risk of asthma later in childhood. And here's the part most parents might not realize — preventing these early infections could make a huge difference in long-term respiratory health.
Researchers from Belgium and Denmark found convincing evidence that babies infected with the respiratory syncytial virus (RSV) during their first few months of life are far more likely to develop asthma as they grow older. This risk is especially pronounced for children who have a family history of asthma or allergies, painting a complex picture of how genetics and early-life health experiences interact.
The findings, published in Science Immunology, suggest that protecting newborns from RSV may significantly reduce asthma rates across the population. Professor Bart Lambrecht of the Flanders Institute for Biotechnology (VIB) and Ghent University explained, “Childhood asthma has many roots, but early RSV infection combined with genetic allergy risks seems to steer the immune system in a direction that favors asthma. The good news? This chain reaction can be stopped.”
To uncover this connection, the research team analyzed extensive Danish population health data covering all children and their parents, alongside tightly controlled laboratory studies. Together, these datasets showed that when a baby with an inherited allergy risk is exposed to RSV early on, it creates a sort of ‘immune overreaction’ pattern. The immune cells start responding too strongly to everyday allergens — like dust mites — setting the stage for asthma later.
If asthma or allergy already runs in the family, the danger compounds even more. Antibodies passed from parent to newborn can make the baby’s immune system extra sensitive to allergens, multiplying the overall risk. Yet, when newborns were shielded from RSV in experimental models, this harmful immune shift did not occur — and asthma did not develop.
Professor Hamida Hammad of VIB-Ghent University believes this has major public health implications. “With RSV prevention becoming more available, we’re no longer only talking about avoiding hospital stays,” she said. “We could actually reshape the long-term respiratory health trajectory for countless children.”
Preventive strategies are already emerging, including maternal RSV vaccines administered during the third trimester and passive immunization for newborns using long-acting antibodies. However, despite their proven ability to prevent severe RSV-related hospitalizations, adoption remains staggered across countries.
“This is a crucial moment for collaboration between scientists, pediatricians, and policymakers,” Lambrecht urged. “If stopping RSV in infancy can also reduce asthma cases, the overall health and economic benefits could be enormous.”
But here’s a point that might stir debate: should widespread RSV prevention be prioritized primarily as an asthma prevention strategy? Some may question if the data yet justify it, while others argue the evidence is strong enough to act now. What do you think — should healthcare systems move faster to integrate RSV immunization programs for newborns? Share your thoughts in the comments below.
